Goldman Sachs has begun coverage of Sanofi, listed on NASDAQ as SNY, with a neutral rating. The bank acknowledged that the French pharmaceutical company is “emerging as a pipeline story” but emphasized the need for additional data from its drug candidates before adopting a more favorable stance. Goldman Sachs has set a price target of $65 for Sanofi’s stock, representing an approximate 13% potential increase.
Goldman Sachs Rates Sanofi Neutral, Citing Need for Pipeline Successes
Related stories
Latest News
Democrats Criticize SBA’s Plan to Move Six Regional Offices
A group of 24 House Democrats has criticized the...
Technology
Yahoo Remains Active with Ambitious AI Plans
In September 2021, Jim Lanzone assumed the role of...
Finance News
Amazon Recalls Laundry Detergent Over Bacteria Contamination Concerns
The U.S. Consumer Product Safety Commission (CPSC) has announced...
Business
Hundreds of New Yorkers line up for free eggs; all gone in 10 minutes.
On Friday, large crowds gathered at three locations in...
Technology
Anduril considers establishing a weapons factory in the UK
Factories are currently gaining significant attention in the defense...
DMN8 Partnershttps://salvonow.com/
DMN8 Partners utilizes a strategy of Cross Channel marketing including local search engine optimization, PPC, messaging and hyper-targeted audiences allow our clients to experience results and ROI that fuel growth and expansion in their operations. There are a lot of digital marketing options across the country but partnering with an agency that understands multiple touches on multiple platforms allows your company’s message to be seen at the perfect time, on the perfect platform, by your perfect prospect. DMN8 Partners has had years of experience growing businesses. Start growing your business today and begin DOMINATE-ing your market.